NCT06225843: An ongoing trial by Alethia Biotherapeutics
This trial is ongoing. It must report results 1 year, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06225843 |
|---|---|
| Title | A Proof-of-Concept Phase II Trial to Evaluate the EMT Inhibitor Sotevtamab Combined With FOLFOX Administered as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 15, 2024 |
| Completion date | March 31, 2026 |
| Required reporting date | March 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |